Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report

被引：1

作者：

Matsuura, Hiroaki ^{[1
]}

Higo, Hisao ^{[1
]}

Kuribayashi, Tadahiro ^{[1
]}

Tamaoki, Akihiko ^{[2
]}

Nakasuka, Takamasa ^{[1
]}

Uno, Mari ^{[1
]}

Makimoto, Go ^{[1
]}

Ninomiya, Kiichiro ^{[1
]}

Fujii, Masanori ^{[1
]}

Rai, Kammei ^{[1
]}

Ichihara, Eiki ^{[1
]}

Hotta, Katsuyuki ^{[1
]}

Miyahara, Nobuaki ^{[1
]}

Tabata, Masahiro ^{[1
]}

Maeda, Yoshinobu ^{[3
]}

Kiura, Katsuyuki ^{[1
]}

Ohashi, Kadoaki ^{[1
]}

机构：

[1] Okayama Univ Hosp, cho Kita Ward, 2 5 1 Shikata cho Kita Ward, Okayama 7008558, Japan

[2] Okayama Hlth Fdn Hosp, Okayama Hlth Fdn, Okayama 7000952, Japan

[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med, Okayama, Japan

来源：

THORACIC CANCER | 2024年 / 15卷 / 17期

关键词：

case report; EGFR-mutated lung cancer; osimertinib; pulmonary tuberculosis; rifampicin; GEFITINIB;

D O I：

10.1111/1759-7714.15324

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

引用

页码：1390 / 1394

页数：5

共 50 条

[1] Adjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer
Gassa, Asmae
Ozkan, Filiz
Alakus, Hakan
Bruns, Christiane
ONKOLOGE, 2021, 27 (02): : 172 - 173
[2] Osimertinib in EGFR-Mutated Lung Cancer REPLY
Herbst, Roy S.
Wu, Yi-Long
Tsuboi, Masahiro
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 676
[3] Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
Crowley, Fionnuala
Fitzgerald, Bailey G.
Bhardwaj, Aarti S.
Siraj, Irine
Smith, Cardinale
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
[4] Severe cardiotoxicity induced by osimertinib in a patient with EGFR-mutated adenocarcinoma of the lung
Tanaka, Takaaki
Nii, Soma
Yamaoka, Hidenaru
Fujimoto, Nobukazu
BMJ CASE REPORTS, 2023, 16 (07)
[5] OsimertinibAcquired resistance in EGFR-mutated lung cancer: case report
Reactions Weekly, 2021, 1836 (1) : 619 - 619
[6] Combination Therapy for EGFR-Mutated Lung Cancer
Wu, Yi-Long
Zhou, Qing
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 2005 - 2007
[7] Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer
Kim, Edward S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 370 - 370
[8] Adjuvante Therapie mit Osimertinib bei operablem EGFR-mutiertem LungenkarzinomAdjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer
Asmae Gassa
Filiz Özkan
Hakan Alakus
Christiane Bruns
Der Onkologe, 2021, 27 (2): : 172 - 173
[9] Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).
Breadner, Daniel Adam
Vincent, Mark David
Liu, Geoffrey
Rothenstein, Jeffrey
Menjak, Ines B.
Cheema, Parneet Kaur
Juergens, Rosalyn A.
Mithoowani, Hamid
Bains, Puneet
Wang, Ying
Wheatley-Price, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Wu, Yi-Long
Tsuboi, Masahiro
He, Jie
John, Thomas
Grohe, Christian
Majem, Margarita
Goldman, Jonathan W.
Laktionov, Konstantin
Kim, Sang-We
Kato, Terufumi
Vu, Huu-Vinh
Lu, Shun
Lee, Kye-Young
Akewanlop, Charuwan
Yu, Chong-Jen
de Marinis, Filippo
Bonanno, Laura
Domine, Manuel
Shepherd, Frances A.
Zeng, Lingmin
Hodge, Rachel
Atasoy, Ajlan
Rukazenkov, Yuri
Herbst, Roy S.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723

← 1 2 3 4 5 →